The DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: If not promptly recognized, endocrine dysfunction can be life threatening. The incidence and risk of developing such adverse events (AEs) following the use of immune checkpoint inhibitor (ICI) regimens are unknown. OBJECTIVE: To compare the incidence and risk of endocrine AEs following treatment with US Food and Drug Administration-approved ICI regimens. DATA SOURCES: A PubMed search through July 18, 2016, using the following keywords was performed: "ipilimumab," "MDX-010," "nivolumab," "BMS-963558," "pembrolizumab," "MK-3475," "atezolizumab," "MPDL3280A," and "phase." STUDY SELECTION: Thirty-eight randomized clinical trials evaluating the usage of these ICIs for treatment of advanced solid tumors were identified, resulting in a total of 7551 patients who were eligible for a meta-analysis. Regimens were categorized by class into monotherapy with a PD-1 (programmed cell death protein 1) inhibitor, a CTLA-4 (cytotoxic T-lymphocyte-associated protein-4) inhibitor, or a PD-L1 (programmed cell death 1 ligand 1) inhibitor, and combination therapy with PD-1 plus CTLA-4 inhibitors. DATA EXTRACTION AND SYNTHESIS: The data were extracted by 1 primary reviewer (R.B.-S.) and then independently reviewed by 2 secondary reviewers (W.T.B. and A.C.G.-C.) following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Inferences on the incidence of AEs were made using log-odds random effects models. MAIN OUTCOMES AND MEASURES: Incidence of all-grade hypothyroidism, hyperthyroidism, hypophysitis, primary adrenal insufficiency, and insulin-deficient diabetes. RESULTS: Overall, 38 randomized clinical trials comprising 7551 patients were included in this systematic review and meta-analysis. The incidence of both hypothyroidism and hyperthyroidism was highest in patients receiving combination therapy. Patients on the combination regimen were significantly more likely to experience hypothyroidism (odds ratio [OR], 3.81; 95% CI, 2.10-6.91, P < .001) and hyperthyroidism (OR, 4.27; 95% CI, 2.05-8.90; P = .001) than patients on ipilimumab. Compared with patients on ipilimumab, those on PD-1 inhibitors had a higher risk of developing hypothyroidism (OR, 1.89; 95% CI, 1.17-3.05; P = .03). The risk of hyperthyroidism, but not hypothyroidism, was significantly greater with PD-1 than with PD-L1 inhibitors (OR, 5.36; 95% CI, 2.04-14.08; P = .002). While patients who received PD-1 inhibitors were significantly less likely to experience hypophysitis than those receiving ipilimumab (OR, 0.29; 95% CI, 0.18-0.49; P < .001), those who received combination therapy were significantly more likely to develop it (OR, 2.2; 95% CI, 1.39-3.60; P = .001). For primary adrenal insufficiency and insulin-deficient diabetes no statistical inferences were made due to the smaller number of events. CONCLUSIONS AND RELEVANCE: Our study provides more precise data on the incidence of endocrine dysfunctions among patients receiving ICI regimens. Patients on combination therapy are at increased risk of thyroid dysfunction and hypophysitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The occurrence of AI in ICI users has been reported in about 1% of cases and more frequently in individuals receiving combination regimens like anti-CTLA4 plus anti-PD1/PD-L1 agents (4%-8%) (25, 28, 29).”
From The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While hypothyroidism and thyrotoxicosis have been mainly associated with anti-PD1/PDL1 agents (especially in a combination regimen with anti-CTLA4, co-occurring with hepatobiliary and respiratory irAEs), hypophysitis, AI, and hypopituitarism were more frequently reported with anti-CTLA4 drugs (ipilimumab) (25, 26).”
From The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ICI-diabetes is an insulin-deficient phenotype that presents as acute severe hyperglycemia or DKA and appears to occur more abruptly than type 1 diabetes (216-218).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [217]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Immune checkpoint inhibitors (ICIs) (agents that block programmed cell death protein 1 [PD-1] and programmed cell death protein ligand 1 [PD-L1]) suppress physiologic blocks on immune responses, which can result in autoimmune toxicities, including autoimmune diabetes (incidence approximately #1%).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Research works printed but not linked: 1
- Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830.
Cited by
Sorted by citations
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,536
Global epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491
A review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,396
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Aguilera, J. V., Chintakuntlawar, A. V., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 889
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Nanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6650 · Cited by 710
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L., Barroso‐Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 550
Exosome-based immunotherapy: a promising approach for cancer treatment
Xu, Z., Zeng, S., Gong, Z., & Yan, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01278-3 · Cited by 482
Faje, A. T., Lawrence, D., Flaherty, K., Freedman, C., Fadden, R., Rubin, K., Cohen, J., & Sullivan, R. J. (2018) · Cancer · doi:10.1002/cncr.31629 · Cited by 486
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 495
de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381
Husebye, E. S., Pearce, S. H., Krone, N. P., & Kämpe, O. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00136-7 · Cited by 378
Wojtukiewicz, M. Z., Rek, M. M., Karpowicz, K., Górska, M., Polityńska, B., Wojtukiewicz, A. M., Moniuszko, M., Radziwon, P., Tucker, S. C., & Honn, K. V. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09976-0 · Cited by 373
Choi, J., & Lee, S. Y. (2020) · Immune Network · doi:10.4110/in.2020.20.e9 · Cited by 309
Safety of combining radiotherapy with immune-checkpoint inhibition
Hwang, W. L., Pike, L., Royce, T. J., Mahal, B. A. V., & Loeffler, J. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0046-7 · Cited by 299
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Sullivan, R. J., & Weber, J. S. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00259-5 · Cited by 312
Wei, S. C., Meijers, W. C., Axelrod, M. L., Anang, N.-A. A. S., Screever, E. M., Wescott, E. C., Johnson, D. B., Whitley, E., Lehmann, L., Courand, P.-Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0856 · Cited by 290
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
de Filette, J. M. K., Pen, J. J., Decoster, L., Vissers, T. F. H., Bravenboer, B., der Auwera, B. J. R. V., Gorus, F., Roep, B. O., Aspeslagh, S., Neyns, B., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0291 · Cited by 284
An update on the pathogenesis of Hashimoto’s thyroiditis.
Weetman, A. P. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01477-1 · Cited by 258
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Wang, Y., Zhang, H., Liu, C., Wang, Z., Wu, W., Zhang, N., Zhang, L., Hu, J. J., Luo, P., Zhang, J., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01325-0 · Cited by 273
Rushworth, R. L., Torpy, D. J., & Falhammar, H. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1807486 · Cited by 262
Kundu, M., Butti, R., Panda, V. K., Malhotra, D., Das, S., Mitra, T., Kapse, P., Gosavi, S., & Kundu, G. C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01990-4 · Cited by 284
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis
Wiersinga, W. M., Poppe, K. G., & Effraimidis, G. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00005-0 · Cited by 254
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Ralli, M., Botticelli, A., Visconti, I. C., Angeletti, D., Fiore, M., Marchetti, P., Lambìase, A., VINCENTIIS, M. D., & Greco, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9235638 · Cited by 254
Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus
Clotman, K., Janssens, K., Specenier, P. M., Weets, I., & Block, C. E. M. D. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00728 · Cited by 237
Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes
Kotwal, A., Haddox, C., Block, M., & Kudva, Y. C. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000591 · Cited by 228
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Hahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Muir, C. A., Clifton-Bligh, R. J., Long, G. V., Scolyer, R. A., Lo, S., Carlino, M. S., Tsang, V., & Menzies, A. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab263 · Cited by 217
Imaging of Cancer Immunotherapy: Current Approaches and Future Directions
Nishino, M., Hatabu, H., & Hodi, F. S. (2018) · Radiology · doi:10.1148/radiol.2018181349 · Cited by 218
Immune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 219
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors
Vogrig, A., Fouret, M., Joubert, B., Picard, G., Rogemond, V., Pinto, A., Muñiz‐Castrillo, S., Roger, M., Raimbourg, J., Dayen, C., et al. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000604 · Cited by 198
Zhai, Y., Ye, X., Hu, F., Xu, J., Guo, X., Zhuang, Y., & He, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0754-2 · Cited by 195
Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes
Quandt, Z., Young, A., & Anderson, M. S. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13424 · Cited by 192
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 213
Tan, M. H., Iyengar, R., Mizokami-Stout, K., Yentz, S., MacEachern, M. P., Shen, L. Y., Redman, B., & Gianchandani, R. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0073-4 · Cited by 172
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
Kotwal, A., Kottschade, L. A., & Ryder, M. M. (2019) · Thyroid · doi:10.1089/thy.2019.0250 · Cited by 168
Gougis, P., Jochum, F., Abbar, B., Dumas, E., Bihan, K., Lebrun-Vignes, B., Moslehi, J., Spano, J.-P., Laas, E., Hotton, J., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102536 · Cited by 161
Immune checkpoint inhibitor toxicities
Marin-Acevedo, J. A., Chirila, R. M., & Dronca, R. S. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.03.012 · Cited by 160
Burch, H. B. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1901214 · Cited by 164
A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
Chhabra, N., & Kennedy, J. M. (2021) · Journal of Medical Toxicology · doi:10.1007/s13181-021-00833-8 · Cited by 155
French Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140
Checkpoint Inhibitor–Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes
Tsang, V., McGrath, R. T., Clifton-Bligh, R. J., Scolyer, R. A., Jakrot, V., Guminski, A. D., Long, G. V., & Menzies, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00423 · Cited by 143
Sex Hormones and Anticancer Immunity
Özdemir, B. C., & Dotto, G. P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0137 · Cited by 134
Stelmachowska‐Banaś, M., & Czajka-Oraniec, I. (2020) · Endocrine Connections · doi:10.1530/ec-20-0342 · Cited by 139
Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment
Dalmazi, G. D., Ippolito, S., Lupi, I., & Caturegli, P. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1701434 · Cited by 134
Clinical and translational attributes of immune-related adverse events
Suijkerbuijk, K. P. M., van Eijs, M. J. M., van Wijk, F., & Eggermont, A. M. M. (2024) · Nature Cancer · doi:10.1038/s43018-024-00730-3 · Cited by 136
Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
Wright, J. J., Salem, J., Johnson, D. B., Lebrun‐Vignes, B., Stamatouli, A. M., Thomas, J. W., Herold, K. C., Moslehi, J. J., & Powers, A. C. (2018) · Diabetes Care · doi:10.2337/dc18-1465 · Cited by 127
Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis
Grouthier, V., Lebrun-Vignes, B., Moey, M., Johnson, D. B., Moslehi, J. J., Salem, J.-E., & Bachelot, A. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0555 · Cited by 126
Girotra, M., Hansen, A. R., Farooki, A., Byun, D. J., Min, L., Creelan, B., Callahan, M. K., Atkins, M. B., Sharon, E., Antonia, S. J., et al. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky021 · Cited by 131
Immune Checkpoint Inhibitor Toxicity
Palmieri, D. J., & Carlino, M. S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0718-6 · Cited by 126
von Itzstein, M. S., Khan, S., & Gerber, D. E. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa081 · Cited by 121
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Jia, X., Geng, L., Jiang, P., Xu, H., Nan, K., Yao, Y., Jiang, L., Sun, H., Qin, T., & Guo, H. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01749-x · Cited by 120
George, J., Bajaj, D., Sankaramangalam, K. P., Yoo, J. W., Joshi, N. S., Gettinger, S. N., Price, C. C., & Farrell, J. J. (2019) · Pancreatology · doi:10.1016/j.pan.2019.04.015 · Cited by 118
Heinzerling, L., Toni, E. D., Schett, G. A., Hundorfean, G., & Zimmer, L. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0119 · Cited by 123
Gubbi, S., Hannah‐Shmouni, F., Verbalis, J. G., & Koch, C. A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101371 · Cited by 118
Barroso‐Sousa, R., Ott, P. A., Hodi, F. S., Kaiser, U. B., Tolaney, S. M., & Min, L. (2018) · Cancer · doi:10.1002/cncr.31200 · Cited by 122
Chaker, L., Cooper, D. S., Walsh, J. P., & Peeters, R. P. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02016-0 · Cited by 143
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 115
An Update on Addison’s Disease
Barthel, A., Benker, G., Berens, K., Diederich, S., Manfras, B. J., Grüber, M., Kanczkowski, W., Kline, G. A., Kamvissi, V., Hahner, S., et al. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0804-2715 · Cited by 115
Ji, H., Tang, X., Dong, Z. W., Song, L., & Jia, Y. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-018-0735-0 · Cited by 113
Arima, H., Iwama, S., Inaba, H., Ariyasu, H., Makita, N., Otsuki, M., Kageyama, K., Imagawa, A., & Akamizu, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0163 · Cited by 108
Zhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.014 · Cited by 103
Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
Baraibar, I., Melero, I., Ponz‐Sarvisé, M., & Álvarez, E. C. (2019) · Drug Safety · doi:10.1007/s40264-018-0774-8 · Cited by 106
Cardiometabolic Comorbidities in Cancer Survivors
Zullig, L. L., Sung, A. D., Khouri, M. G., Jazowski, S. A., Shah, N. P., Sitlinger, A. P., Blalock, D. V., Whitney, C. A., Kikuchi, R., Bosworth, H. B., et al. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.03.005 · Cited by 105
Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
Al-Jundi, M., Thakur, S., Gubbi, S., & Kłubo-Gwieździńska, J. (2020) · Cancers · doi:10.3390/cancers12082104 · Cited by 105
Adrenal insufficiency: Physiology, clinical presentation and diagnostic challenges
Martin‐Grace, J., Dineen, R., Sherlock, M., & Thompson, C. J. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.01.029 · Cited by 112
TIGIT, a novel immune checkpoint therapy for melanoma
Tang, W., Chen, J., Ji, T., & Cong, X. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05961-3 · Cited by 109
Lee, D. J., Lee, H. J., Farmer, J. R., & Reynolds, K. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01530-2 · Cited by 104
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
Wu, Z., Chen, Q., Qu, L., Li, M., Wang, L., Mir, M. C., Carbonara, U., Pandolfo, S. D., Black, P. C., Paul, A. K. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.01.028 · Cited by 99
Identifying and managing the adverse effects of immune checkpoint blockade
Winer, A., Bodor, J. N., & Borghaei, H. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.111 · Cited by 96
Piranavan, P., Li, Y., Brown, E. M., Kemp, E. H., & Trivedi, N. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01151 · Cited by 98
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
Garutti, M., Lambertini, M., & Puglisi, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100276 · Cited by 101
Cheung, Y.-M. M., Wang, W., McGregor, B. A., & Hamnvik, O. R. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03128-7 · Cited by 101
Immune checkpoint inhibitors and risk of type 1 diabetes
Chen, X., Affinati, A. H., Lee, Y., Turcu, A. F., Henry, N. L., Schiopu, E., Qin, A., Othus, M., Clauw, D., Ramnath, N., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2213 · Cited by 93
Immunotherapy toxicity: identification and management
Gumusay, O., Callan, J., & Rugo, H. S. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06480-5 · Cited by 98
Yano, S., Ashida, K., Sakamoto, R., Sakaguchi, C., Ogata, M., Maruyama, K., Sakamoto, S., Ikeda, M., Ohe, K., Akasu, S., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.049 · Cited by 92
Casagrande, S., Sopetto, G. B., Bertalot, G., Bortolotti, R., Racanelli, V., Caffo, O., Giometto, B., Berti, A., & Veccia, A. (2024) · Cancers · doi:10.3390/cancers16071440 · Cited by 100
Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review
Iglesias, P., Sánchez, J. C., & Díez, J. J. (2021) · Pituitary · doi:10.1007/s11102-021-01141-8 · Cited by 90
Khan, Z., Hammer, C., Carroll, J., Nucci, F. D., Acosta, S. L., Maiya, V., Bhangale, T., Hunkapiller, J., Mellman, I., Albert, M. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23661-4 · Cited by 83
Interleukin-15 in autoimmunity
Allard‐Chamard, H., Mishra, H. K., Nandi, M., Mayhue, M., Menéndez, A., Ilangumaran, S., & Ramanathan, S. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155258 · Cited by 84
Emens, L. A., Adams, S., Cimino‐Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K. M., McArthur, H. L., Mittendorf, E. A., Nanda, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002597 · Cited by 84
Preiato, V. L., Salvagni, S., Ricci, C., Ardizzoni, A., Pagotto, U., & Pelusi, C. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09618-w · Cited by 83
Role of Immunotherapy in Breast Cancer
Jacob, S. L., Huppert, L. A., & Rugo, H. S. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00483 · Cited by 81
Da, L., Teng, Y., Wang, N., Zaguirre, K., Liu, Y., Qi, Y., & Song, F. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01671 · Cited by 84
Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
Xu, Y., Fu, Y., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02023 · Cited by 83
Majd, N., Waguespack, S. G., Jankú, F., Fu, S., Peñas-Prado, M., Xu, M., Alshawa, A., Kamiya-Matsuoka, C., Raza, S. M., McCutcheon, I. E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001532 · Cited by 83
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
Goswami, M., Gui, G., Dillon, L. W., Lindblad, K. E., Thompson, J., Valdez, J., Kim, D., Ghannam, J. Y., Oetjen, K. A., DeStefano, C. B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003392 · Cited by 84
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
Jessel, S., Weiss, S. A., Austin, M., Mahajan, A. K., Etts, K., Zhang, L., Aizenbud, L., Perdigoto, A. L., Hurwitz, M. E., Sznol, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836859 · Cited by 79
Rivero, J. D., Cordes, L. M., Kłubo-Gwieździńska, J., Madan, R. A., Nieman, L. K., & Gulley, J. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0470 · Cited by 79
Immune checkpoint inhibitor-related thyroid dysfunction
Iwama, S., Kobayashi, T., Yasuda, Y., & Arima, H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101660 · Cited by 76
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders
Jannin, A., Penel, N., Ladsous, M., Vantyghem, M., & Cao, C. D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.015 · Cited by 77
Damlaj, M., Fakih, R. O. E., & Hashmi, S. K. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.07.003 · Cited by 75
Sol, B., de Filette, J. M. K., Awada, G., Raeymaeckers, S., Aspeslagh, S., Andreescu, C. E., Neyns, B., & Velkeniers, B. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0151 · Cited by 74
Metadata
- Authors
- Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M.
- Affiliations
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Tolaney, Sara M.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-02-01
- Volume
- 4
- Issue
- 2
- Pages
- 173
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC5838579
- OpenAlex
- W2760410509
- Cited by
- 1,115
- References
- 67
- Citations by year
- 2026: 113 · 2025: 134 · 2024: 116 · 2023: 138 · 2022: 173 · 2021: 150 · 2020: 150 · 2019: 93 · 2018: 46
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- JAMA Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- endocrine adverse events, immune checkpoint inhibitors, hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency, insulin-deficient diabetes, PD-1 inhibitors, CTLA-4 inhibitors, PD-L1 inhibitors, combination immunotherapy, ipilimumab, nivolumab, pembrolizumab, atezolizumab, advanced solid tumors, adverse event incidence, randomized controlled trials
- MeSH terms
- Antineoplastic Agents, Immunological, Antibodies, Monoclonal, Endocrine System Diseases, Endocrine Glands, Humans, Immunotherapy, Neoplasms, Incidence, Randomized Controlled Trials as Topic, Protein Kinase Inhibitors, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
